RxDoctor Payments DataLook up a doctor →

Robert Hart, MD

Family Medicine · Hickory, NCNPI 1326044504

Payments from drug & device makers

$636,229in general payments, 2019–2025

Across 383 payments — averaging $1661.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hoffmann-la Roche Limited$238K
  • Orasure Technologies Inc.$124K
  • Pfizer$120K
  • Genentech, Inc.$82K
  • F. Hoffmann-la Roche AG$39K
  • Boehringer Ingelheim Canada Ltd.ltee$25K
  • plus $7K from 38 others

What the payments were for

  • Food & beverage$5,11299%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$636,229 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$59,000
Medicare patients
195
Services billed
633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin63$69,426
EliquisApixaban66$45,103
RybelsusSemaglutide11$26,888
InvokanaCanagliflozin27$23,439
FarxigaDapagliflozin Propanediol26$17,923
XareltoRivaroxaban13$12,185
ShingrixVaricella-Zoster Ge/As01b/Pf44$9,735
TradjentaLinagliptin11$5,252
Lisdexamfetamine Dimesylate11$4,318
Atorvastatin Calcium340$3,153
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$3,057
Testosterone Cypionate39$2,375
Tamsulosin Hcl126$2,041
Metformin Hcl266$1,988
Levothyroxine Sodium234$1,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$2,313$74,67774 claims
PfizerEliquis$120,231$45,10366 claims
Johnson & JohnsonInvokana, Xarelto$400$35,62440 claims
Novo NordiskRybelsus$599$26,88811 claims
AstraZenecaFarxiga$849$17,92326 claims
GSKShingrix$206$9,73544 claims
AbbVieSynthroid$190$1,63919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →